Immuno-PET developer ImaginAB has licensed its zirconium-89 (Zr-89) crefmirlimab berdoxam radiotracer to biotech company Leucid for use in studies of solid tumors.
Zr-89 crefmirlimab berdoxam (CD8 ImmunoPET) is designed to bind to CD8 receptors on T cells on PET imaging. The technique is currently being investigated for diagnosing the immune status of a patient, measuring the efficacy of immunotherapies, and predicting patient outcomes, according to the company.
Under the terms of the agreement, ImaginAb will license and supply clinical doses of CD8 ImmunoPET tracer to Leucid for use in conjunction with CAR-T cell immunotherapies.
